Devonian Health Group Inc (GSD) - Total Assets
Based on the latest financial reports, Devonian Health Group Inc (GSD) holds total assets worth CA$8.63 Million CAD (≈ $6.24 Million USD) as of April 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Devonian Health Group Inc - Total Assets Trend (2015–2025)
This chart illustrates how Devonian Health Group Inc's total assets have evolved over time, based on quarterly financial data. Also see GSD market cap overview for the company's overall valuation and market capitalisation.
Devonian Health Group Inc - Asset Composition Analysis
Current Asset Composition (July 2025)
Devonian Health Group Inc's total assets of CA$8.63 Million consist of 55.1% current assets and 44.9% non-current assets. Review Devonian Health Group Inc (GSD) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 44.1% |
| Accounts Receivable | CA$475.88K | 3.0% |
| Inventory | CA$34.51K | 0.2% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$4.90 Million | 31.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Devonian Health Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Devonian Health Group Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Devonian Health Group Inc's current assets represent 55.1% of total assets in 2025, an increase from 18.6% in 2015.
- Cash Position: Cash and equivalents constituted 44.1% of total assets in 2025, up from 8.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, a decrease from 41.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 31.0% of total assets.
Devonian Health Group Inc Competitors by Total Assets
Key competitors of Devonian Health Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
USA | $910.22 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Devonian Health Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.12 | 0.37 |
| Quick Ratio | 0.99 | 1.12 | 0.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-5.18K | CA$1.74 Million | CA$-1.15 Million |
Devonian Health Group Inc - Advanced Valuation Insights
This section examines the relationship between Devonian Health Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.09 |
| Latest Market Cap to Assets Ratio | 1.14 |
| Asset Growth Rate (YoY) | -48.5% |
| Total Assets | CA$15.83 Million |
| Market Capitalization | $18.00 Million USD |
Valuation Analysis
Above Book Valuation: The market values Devonian Health Group Inc's assets above their book value (1.14x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Devonian Health Group Inc's assets decreased by 48.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Devonian Health Group Inc (2015–2025)
The table below shows the annual total assets of Devonian Health Group Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-07-31 | CA$15.83 Million ≈ $11.45 Million |
-48.49% |
| 2024-07-31 | CA$30.73 Million ≈ $22.23 Million |
+60.26% |
| 2023-07-31 | CA$19.18 Million ≈ $13.87 Million |
-11.16% |
| 2022-07-31 | CA$21.59 Million ≈ $15.62 Million |
+47.77% |
| 2021-07-31 | CA$14.61 Million ≈ $10.57 Million |
-12.51% |
| 2020-07-31 | CA$16.70 Million ≈ $12.08 Million |
-2.63% |
| 2019-07-31 | CA$17.15 Million ≈ $12.40 Million |
-10.49% |
| 2018-07-31 | CA$19.16 Million ≈ $13.86 Million |
+65.75% |
| 2017-07-31 | CA$11.56 Million ≈ $8.36 Million |
+14.73% |
| 2016-07-31 | CA$10.07 Million ≈ $7.29 Million |
+11410.58% |
| 2016-06-30 | CA$87.52K ≈ $63.31K |
-99.25% |
| 2015-07-31 | CA$11.73 Million ≈ $8.49 Million |
-- |
About Devonian Health Group Inc
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for At… Read more